Efficacy and safety of antiplatelet therapy in COVID-19: Insights from a meta-analysis of randomized controlled trials

作者全名："Kao, Guoying; Chen, Yunlin; Fan, Jinqi"

作者地址："[Kao, Guoying] Chongqing Univ, Chongqing Emergency Med Ctr, Dept Cardiovasc Med, Cent Hosp, Chongqing, Peoples R China; [Chen, Yunlin; Fan, Jinqi] Chongqing Med Univ, Dept Cardiol, Affiliated Hosp 2, Chongqing, Peoples R China; [Fan, Jinqi] Chongqing Med Univ, Affiliated Hosp 2, Chongqing Cardiac Arrhythmias Serv Ctr, Dept Cardiol, Chongqing 400010, Peoples R China"

通信作者："Fan, JQ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Chongqing Cardiac Arrhythmias Serv Ctr, Dept Cardiol, Chongqing 400010, Peoples R China."

来源：INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001183568000001

JCR分区：Q4

影响因子：0.9

年份：2024

卷号：62

期号：5

开始页：195

结束页：203

文献类型：Article

关键词：antiplatelet therapy; COVID-19-; meta-analysis; thrombosis; bleeding

摘要："Background: COVID-19 induces a pro-coagulant state with thrombotic events. This meta-analysis explores the efficacy and safety of antiplatelet-based therapy in COVID-19 patients through randomized controlled trials (RCTs). Materials and methods: A systematic literature search until March 10, 2023, identified 7 RCTs involving 23,415 inpatients. Of these, 11,891 received antiplatelet-based treatment, and tistical analysis was performed using Review Manager 5.4. Results: The included trials involved patients with a mean age ranging from 54.3 to 62.0 years and a prevalence of hypertension ranging from 10.9 to 65.0% and coronary artery disease ranging from 3.2 to 32.7%. The pooled analysis showed no significant difference in overall mortality between groups (RR 1.0, 95% CI 0.99 - 1.01, p = 0.76). However, antiplatelet therapy significantly reduced major thrombotic events (RR 0.86, 95% CI 0.75 - 0.99, p = 0.04). Conversely, it increased major bleeding risks (RR 1.62, 95% CI 1.24 - 2.12, p = 0.0005). There was no significant difference in the incidence of invasive mechanical ventilation and retherapy does not confer mortality benefit in COVID-19 patients but lowers major thromrisks. Ongoing large RCTs will provide more therapy."

基金机构：Gen-eral Program of Health and Family Plan-ning Commission of Chongqing [2015MSXM020]; Program for Innovative Research Team of Chongqing Kuanren Hospital

基金资助正文："This study was supported by the Gen-eral Program of Health and Family Plan-ning Commission of Chongqing (Grant No. 2015MSXM020, Fan JQ) , and the Program for Innovative Research Team of Chongqing Kuanren Hospital."